CTD Holdings, Inc. (OTCQB: CTDH), a distributor and manufacturer of cyclodextrin
products including the orphan drug designated Trappsol® Cyclo™, today
announced that President and Director Dr. Jeffrey Tate has been named Chairman
of the 18th International Cyclodextrin Symposium to be held in Gainesville, Fla.
in 2016. The Symposium Advisory Board reviewed three proposals to host the 2016
meeting and selected Dr. Tate's presentation based on the extensive preparation
that has already been done. "I am delighted that our proposal was selected from
a strong field," Dr. Tate said. "Researchers and businesses in Gainesville
played important roles in the early days of cyclodextrin commercialization.
Holding the Symposium here recognizes those historical contributions and the
bright future of cyclodextrins being created by the CTD Holdings Family of
Companies. Our team looks forward to welcoming colleagues from around the
world."


The International Cyclodextrin Symposium is a global gathering of academic and
industry researchers to present and discuss the latest developments in
cyclodextrin research and applications. Attendees are the opinion leaders in
this rising field of interest; they include biologists, chemists, material
scientists and engineers. The Symposium is held every two years with the venue
selected from proposals solicited by the Advisory Board.


The 18th International Cyclodextrin Symposium will be held at the Hilton
University of Florida Conference Center in Gainesville, May 17-21, 2016. For
further information about registration, sponsorship or presentation
opportunities contact Dr. Tate (service@cyclodex.com).


About the Company: 
The CTD Holdings, Inc. Family of Companies distributes and manufactures the
trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives,
and cyclodextrin complexes for research, nutrition, cosmetic and medical
markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an
orphan drug designated product, for the treatment of Niemann Pick Type C, a
fatal genetic disease in young children. NanoSonic Products, Inc. operates the
world's only cGMP pulse drying facility for the production of ultra-pure
cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin
complexes. CTD, Inc. supplies researchers around the globe from the world's
largest catalog of cyclodextrins. The companies offer a wide variety of
cyclodextrin related manufacturing services to worldwide customers, including
custom formulation, manufacturing, and commercial scale supply of pharmaceutical
grade cyclodextrin complexes. For additional information, visit the Company's
websites: www.ctd-holdings.com and www.cyclodex.com 


Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's
current expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as "anticipates,"
"believes" and "expects" or similar expressions, are forward-looking statements.
These statements are subject to a number of risks, uncertainties and other
factors that could cause actual results in future periods to differ materially
from what is expressed in, or implied by, these statements. The factors which
may influence the Company's future performance include the Company's ability to
obtain additional capital to expand operations as planned, success in attracting
additional customers and profitable contracts, and regulatory risks associated
with producing food and pharmaceutical grade products. These and other risk
factors are described from time to time in the Company's filings with the
Securities and Exchange Commission, including, but not limited to, the Company's
reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no
obligation to update or revise any forward-looking statements as a result of new
information or future events. 



FOR FURTHER INFORMATION PLEASE CONTACT: 

Contact: 
Sitrick And Company
Wendy Tanaka
(415) 369-8447
wtanaka@sitrick.com


Thomas Mulligan
(212) 573-6100, Ext. 395
tmulligan@sitrick.com